News

February 12, 2020February 12, 2020

FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar

News

The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous ... Read more

February 11, 2020February 11, 2020

Mental Health, Education Among Factors Predicting Lack of Response to TNF-alpha Inhibitors in Axial Spondyloarthritis, Study Says

News

Poor mental health, not having a full-time job, spending fewer years in school, and having comorbidities such as hypertension or diabetes all contribute to failure to respond to initial ... Read more

February 7, 2020February 7, 2020

With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus

News

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over ... Read more

February 6, 2020February 6, 2020

Specific Mutations in LTA Gene Determine Risk of Ankylosing Spondylitis, Study Suggests

News

Variations in the LTA gene can alter a person’s risk of developing ankylosing spondylitis (AS), a new study suggests. The study, “Associations of lymphotoxin-a (LTA) rs909253 A/G gene polymorphism, plasma level ... Read more

February 3, 2020February 3, 2020

Early Low Blood Levels of Humira and Antibodies Against It Predict Therapy’s Failure, Study Says

News

Low levels of Humira (adalimumab) early in the course of treatment and the presence of neutralizing autoantibodies in the blood of people with ankylosing spondylitis (AS) are associated with failure ... Read more

January 30, 2020January 30, 2020

AS Patients at Higher Risk of Obstructive Sleep Apnea, Taiwanese Study Finds

News

People with ankylosing spondylitis (AS) are almost three times more likely to develop obstructive sleep apnea (OSA) than healthy individuals, a population-based study in Taiwan shows. The risk is ... Read more

January 27, 2020January 27, 2020

Cosentyx Continues to Ease Symptoms Through 3 Years of Use, New Trial Data Show

News

Treatment with Cosentyx (secukinumab) continues to be safe and to ease symptoms in people with active ankylosing spondylitis (AS) through three years of use, new data from a Phase ... Read more

January 23, 2020January 23, 2020

Altered Gut Microbiome Contributes to Inflammation in Ankylosing Spondylitis, Study Suggests

News

People with ankylosing spondylitis (AS) have an altered composition of microorganisms in their gut, leading to more bacteria that play a role in inflammation and AS progression, a new ... Read more

January 20, 2020January 20, 2020

Health Canada Approves Cimzia for Non-radiographic Axial Spondyloarthritis

News

Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA). The medication is used to treat nr-axSpA patients with evidence ... Read more

January 16, 2020January 16, 2020

Qletli, Biosimilar to Humira, Now Available in China to Treat Certain Autoimmune Diseases

News

Qletli, a biosimilar to Humira (adalimumab), is now available in China for the treatment of three autoimmune diseases, including ankylosing spondylitis (AS). The medication is also approved for the ... Read more

Pin It on Pinterest